Empty bench beside a wet winding path in a foggy leafless forest

2026-2027 Flu Shot: When to Get It, Which One, and Is Tamiflu Worth It?

Last winter was rough. If you spent a week in January flat on the couch with a fever of 102 and a cough that hung on into February, you had plenty of company, and there is a decent chance the virus that did it was an H3N2 variant called subclade K.

This year’s flu shots are out, and every strain in them has changed. The federal advisory committee that normally tells everyone what to do is also, for practical purposes, not functioning. So I get a lot of the same three questions this time of year, and I am going to answer them here: when should I get it, which one should I get, and if I catch the flu anyway, is Tamiflu worth taking?

What last season looked like

CDC’s preliminary numbers for 2025-2026 are at least 32 million illnesses, 390,000 hospitalizations, and 24,000 deaths from flu (1). The agency classified the season as moderate for adults and high severity for children. By late May, 174 children had died of flu, and about 85 percent of those who were eligible and had a known vaccination status had not been fully vaccinated (1).

Subclade K was the reason. It surfaced in Australia in July 2025, rode the Southern Hemisphere winter north, and by January it accounted for roughly nine of every ten influenza A viruses sequenced in the United States. It had drifted away from the H3N2 strain in last year’s shot.

The shot still did something. CDC’s interim estimate put vaccine effectiveness against flu-related hospitalization at 30 percent in adults and 41 percent in children and teenagers, with outpatient protection at 22 to 34 percent in adults (2). Those are low numbers by flu vaccine standards. Thirty percent sounds unimpressive until you remember the denominator was 390,000 hospitalizations. I will take a 30 percent cut in my odds of being one of them.

What changed in this year’s shot

All three components were updated for 2026-2027, and the H3N2 piece was swapped specifically to cover subclade K (3). FDA’s advisory committee voted on the strains on March 12, 2026. The egg-based vaccines carry an A/Missouri/11/2025 H1N1 strain, an A/Darwin/1454/2025 H3N2 strain, and a B/Victoria strain; the cell-based and recombinant vaccines use closely matched versions (4).

One thing that trips people up at the pharmacy counter. If the pharmacist says they have four different flu shots, that means four types of vaccine, not four strains. Every flu shot in the U.S. this year covers the same three strains. What differs is how the vaccine is made and how strong a response it produces: standard-dose, high-dose (Fluzone High-Dose), adjuvanted (Fluad), recombinant (Flublok), and cell-based (Flucelvax), plus FluMist and the new mRNA shot. Until a couple of years ago most shots were quadrivalent, meaning they covered four strains. One B lineage, B/Yamagata, has not been confirmed anywhere in the world since March 2020, so FDA dropped it, and every U.S. flu vaccine has been trivalent since the 2024-2025 season.

A small aside, because patients ask. Those place names are where the reference virus was collected, not where the strain came from or where it is worst. “Darwin” means a lab in northern Australia isolated the sample that became the template. Nobody should cancel a trip to the Northern Territory over it.

For what it’s worth, Australia’s 2026 winter has been far quieter than 2025’s, which was the deadliest flu season there this century. Their experts are careful to say a mild Southern Hemisphere season does not reliably predict ours (5). I agree with them. I would not plan around it.

Who is actually making the recommendations this year

This part is messy, and I think you deserve a straight account of it.

In 2025, HHS removed the members of the Advisory Committee on Immunization Practices and appointed new ones. On March 16, 2026, a federal judge in Boston stayed those appointments and the votes the reconstituted committee had taken, finding they likely violated federal law (6). That ruling is on appeal. The practical result is that no functioning ACIP has voted on anything for this fall.

CDC’s response, issued September 1, was to state that the flu recommendations from the July 2025 immunization schedule remain in effect for 2026-2027 (7). In plain terms: annual flu vaccination for everyone 6 months and older, the same as it has been for years. On September 2, the American Academy of Family Physicians, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America published their own respiratory-season guidance, and on flu they all say the same thing (8).

Will your insurance cover it? For flu, almost certainly. Medicare Part B covers the flu shot by statute, and AHIP, the trade group for health insurers, has said its members will keep covering the vaccines that were recommended before the committee was replaced. Flu is the one vaccine with decades of annual guidance behind it, so it is the least disrupted of the three fall shots. COVID and RSV are a different and murkier story, and I covered COVID separately.

September or October? My answer depends on your age

CDC’s guidance for most people is September or October (7). I would push that a little depending on who you are.

If you are under 65 and healthy, get it whenever it is convenient between now and the end of October. There is no advantage in waiting, and the most common way people miss their flu shot is by planning to get it “in a few weeks.”

If you are 65 or older, I would aim for October. Protection from the flu shot fades over the season, and it fades faster in older adults, which is why CDC specifically says to avoid July and August vaccination in this group unless there is no other realistic chance to get it (7). Flu in the U.S. usually peaks somewhere between December and February, so a shot in mid-October puts your best protection squarely over those months, while one in early September has already started to fade by the time the worst of it arrives. Do not let “wait for October” turn into “forgot until January,” though. A September shot beats no shot by a wide margin.

Children between 6 months and 8 years who have never had a flu shot, or have had only one dose ever, need two doses four weeks apart. Start those now so the second dose lands before the end of October.

If you are pregnant, you can get the shot in any trimester (7). A shot in the third trimester also protects the baby for the first months of life, before infants are old enough to be vaccinated themselves.

If you are 65 or older, ask for the stronger shot

I encourage everyone to get a flu shot every year, and I push hardest with older adults and anyone medically fragile. Adults 65 and over should preferentially get one of three vaccines: high-dose (Fluzone High-Dose), recombinant (Flublok), or adjuvanted (Fluad) (7). All three produce a stronger immune response than the standard shot in older adults, whose immune systems respond less to a standard dose. Pharmacies stock them. Ask by name.

There is also something new this year. On August 5, 2026, FDA approved mFlusiva, Moderna’s mRNA flu vaccine and the first of its kind, for adults 50 and older (9). In a phase 3 trial of about 40,700 adults, it was about 27 percent more effective than a standard-dose vaccine at preventing PCR-confirmed flu illness. Approval for ages 50 to 64 is standard. For 65 and older it is accelerated approval, which means Moderna still owes FDA a confirmatory study.

I like it. It is what I have chosen for myself this year, and for the members of my family old enough to get it. One fair caveat: the trial compared it against the standard-dose shot, not against high-dose or adjuvanted, so for people over 65 nobody has shown yet that it beats those. For someone 50 to 64 who wants more than the standard shot, it joins Flublok, which is approved for adults of any age, as a good choice. Coverage may lag, because the usual trigger for insurer coverage of a new vaccine is an ACIP vote, and ACIP is not voting.

Honestly, I am fine with whichever version you are comfortable with. The medical groups put it well: take an enhanced vaccine if one is available, but do not delay vaccination hunting for one (8). The best flu shot is the one you actually get.

FluMist, now at home

FluMist, the nasal spray vaccine, is approved for ages 2 through 49. Since last season, AstraZeneca has shipped it directly to homes through its FluMist Home program, and an adult can give it to themselves or to a child in the household (10). Last season it was free with most commercial insurance plus a shipping fee of about $9, and it was not available in every state. I have not been able to confirm this year’s state list, so check the program site before you plan on it.

One catch. It is a live attenuated vaccine, so it is off the table in pregnancy and for people who are significantly immunocompromised or who live with someone severely immunocompromised. For a household of healthy kids who dread needles, it is a genuinely good option.

If you get the flu anyway: the 48-hour window

This is where telemedicine is the right tool for the job.

Flu antivirals work best when started within 48 hours of the first symptom (11). That window closes fast, because a lot of people spend the first day telling themselves it is only a cold and the second day on hold trying to get an appointment somewhere, and by the time they are seen the 48 hours are gone. A video visit collapses that. When flu is circulating in your area, sudden fever, body aches, and a dry cough are enough to diagnose it clinically without a swab, and the prescription goes to your pharmacy the same hour. A home combination COVID and flu test helps if you have one, but it is not required.

When I see someone for flu symptoms by video, the first thing I ask is whether they have had a positive flu test. Then whether they have been around someone they know had the flu recently. And whether they have had a flu shot this year. If the story fits, I prescribe an antiviral.

Now the honest part, about oseltamivir (Tamiflu). For an otherwise healthy adult, the benefit is modest. Real, but modest. The Cochrane review of the drug’s full clinical study reports found it shortened symptoms by about 17 hours, from roughly 7 days to 6.3 (12). A 2024 meta-analysis in JAMA Internal Medicine found no reduction in hospitalization among outpatients treated with oseltamivir, including older and higher-risk patients, and a clear increase in nausea and vomiting (13). CDC and IDSA still recommend treatment for anyone at higher risk of complications, even after 48 hours, and I do treat those patients past the 48-hour mark. The high-risk group includes adults 65 and older, pregnancy, asthma, COPD, diabetes, heart disease, and a BMI of 40 or above.

For a healthy 30-year-old on day one, I think the fair thing is to lay out those numbers and let the patient decide. Some people will gladly take a day off a week of misery. Others would rather skip the nausea. Both reasonable. When an antiviral makes sense, I prescribe either oseltamivir or baloxavir.

Baloxavir (Xofluza) is the other option: a single dose instead of ten pills over five days, approved for ages 5 and up. In the CENTERSTONE trial, published in the New England Journal of Medicine in 2025, a single dose of baloxavir taken within 48 hours cut household transmission of flu from 13.4 percent to 9.5 percent, a 32 percent reduction in the odds of passing it on (14). That is the first antiviral shown to reduce spread. If you live with a newborn, an elderly parent, or someone on chemotherapy, that result matters. Two caveats. CDC does not recommend baloxavir during pregnancy or breastfeeding, and it is often not covered by insurance the way generic oseltamivir is. Some of my patients prefer it anyway, so before I send it to the pharmacy I let them know there may be an out-of-pocket cost.

For patients

Get the shot. If you are under 65, get it now. If you are 65 or older or have serious medical problems, do not skip it; aim for October, and ask about the high-dose, recombinant, adjuvanted, or mRNA versions. If you are between 50 and 64 and want more than the standard shot, ask your pharmacy about Flublok or mFlusiva, and check whether your plan covers the one you pick.

If you get sick, do not wait to see whether it turns into something. Start a video visit on the first day of symptoms. If you are in a higher-risk group, treatment is worth starting even after 48 hours.

Two things mean you should skip the video visit and be seen in person: trouble breathing, or a fever that improves for a day or two and then comes back with a worse cough. That second pattern can be a bacterial pneumonia following the flu. It is the one I worry about most.

For clinicians

Three practical points for this season. First, with no functioning ACIP, standing orders in many systems reference the July 2025 schedule, and CDC’s September 1 interim guidance is the document to cite if anyone asks what authority you are vaccinating under (7). Second, for your patients 65 and older, the preferential-product recommendation still stands, and mFlusiva was compared against standard dose only, so there is no evidence yet that it outperforms Fluad or high-dose in that group. Third, CENTERSTONE gives you a concrete reason to reach for baloxavir when the index patient lives with someone at high risk, provided the patient is 5 or older, not pregnant, and not severely immunocompromised (14).

On oseltamivir for low-risk outpatients, I think shared decision-making is the honest approach, and the Hanula meta-analysis is worth reading before you tell a healthy 30-year-old it will keep them out of the hospital (13). The evidence for that claim in low-risk patients is weak.

The Bottom Line

The 2026-2027 flu shot has been rebuilt around the H3N2 strain that made last winter so hard, and it is covered and available now. Get it by the end of October. If you are 65 or older, the high-dose, recombinant, adjuvanted, and new mRNA shots are all good choices, and October is the sweet spot for timing. Pick the one you are comfortable with and do not delay hunting for a particular brand. And if you do get the flu, the first 48 hours matter. A video visit on day one is the fastest way to use them.

Related Reading

2026-2027 COVID Vaccine: Who Qualifies, and Do You Need a Doctor’s Note?
Flu Prevention: Vaccines, Symptoms, and Treatment Options
When to Use Telemedicine vs. Urgent Care: How I Spot the Sick One
I hear it almost every day now. “I think I just need a Z-Pak.”

Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.

Sources

  1. Centers for Disease Control and Prevention. Weekly US Influenza Surveillance Report: Key Updates for Week 20, ending May 23, 2026. https://www.cdc.gov/fluview/surveillance/2026-week-20.html
  2. Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness, United States, September 2025–February 2026. MMWR Morb Mortal Wkly Rep. 2026;75(9):116-123. https://pmc.ncbi.nlm.nih.gov/articles/PMC12981535/
  3. Centers for Disease Control and Prevention. 2026-2027 Flu Season. Updated September 2, 2026. https://www.cdc.gov/flu/season/2026-2027.html
  4. U.S. Food and Drug Administration. Influenza Vaccine Composition for the 2026-2027 U.S. Influenza Season. https://www.fda.gov/vaccines-blood-biologics/vaccines/influenza-vaccine-composition-2026-2027-us-influenza-season
  5. Doherty Institute. How severe is this flu season shaping up to be? https://www.doherty.edu.au/articles/how-severe-is-this-flu-season-shaping-up-to-be/
  6. American College of Physicians. Federal Judge Blocks Immunization Schedule Changes, Stays ACIP Member Appointments. March 2026. https://www.acponline.org/acp-newsroom/federal-judge-blocks-immunization-schedule-changes-stays-acip-member-appointments
  7. Centers for Disease Control and Prevention. Interim Clinical Considerations for the Use of Seasonal Influenza Vaccines in the United States. September 1, 2026. https://www.cdc.gov/flu/hcp/vax-summary/seasonal-influenza-vaccines.html
  8. Healthline. U.S. Medical Groups Issue Flu, COVID Vaccine Guidance. September 2026. https://www.healthline.com/health-news/medical-groups-issue-independent-flu-covid-rsv-vaccine-guidance
  9. BioPharma Dive. FDA approves Moderna’s mRNA flu vaccine. August 2026. https://www.biopharmadive.com/news/moderna-fda-approve-mflusiva-seasonal-influenza/826864/
  10. AstraZeneca. FluMist, the nation’s only nasal spray flu vaccine, now available for home delivery. 2025. https://www.astrazeneca-us.com/media/press-releases/2025/FLUMIST-the-nations-only-nasal-spray-flu-vaccine-now-available-for-home-delivery.html
  11. Centers for Disease Control and Prevention. Influenza Antiviral Drug Baloxavir Marboxil. https://www.cdc.gov/flu/treatment/baloxavir-marboxil.html
  12. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014;(4):CD008965. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/full
  13. Hanula R, Bortolussi-Courval É, Mendel A, et al. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2024;184(1):18-27. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2805976
  14. Monto AS, Kuhlbusch K, Bernasconi C, et al. Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza. N Engl J Med. 2025;392(16):1582-1593. https://www.nejm.org/doi/full/10.1056/NEJMoa2413156
Sealed disposable syringes laid out on a blue surface

Measles in 2025: What Patients and Providers Need to Know

The 2025 measles outbreak was one of the most concerning we’d seen in more than a decade. As of March 2025, Texas alone had reported almost 200 confirmed cases, the highest in years. Other states, including New Mexico, Georgia, Kentucky, New Jersey, New York, Pennsylvania, Rhode Island, Washington, California, and Florida, were seeing rising numbers too. Most of those infected were younger than 19, and 95 percent had either not been vaccinated or had an unknown vaccine status. Roughly one in five patients had needed hospitalization by that point. Tragically, one unvaccinated child in Texas had died.

Lower vaccination rates in some communities made it easier for the virus to spread at the time. Clinicians need to stay alert regardless: a cough, fever, and rash in an area with known cases should still raise immediate suspicion for measles.

What Measles Is

Measles is caused by the measles virus, part of the Morbillivirus family. It’s a single-stranded RNA virus that first infects the respiratory tract, then spreads throughout the body.

How It Spreads

The virus is extremely contagious. When someone coughs or sneezes, droplets can hang in the air for up to two hours, and touching a contaminated surface, then your eyes, nose, or mouth, can spread it just as easily.

If someone is exposed and not immune, nine out of ten will get sick. People with measles can spread the virus four days before the rash starts and four days after. That’s one reason outbreaks move so quickly.

The infectiousness of a virus is often measured by R0. For measles, in an unvaccinated community, R0 runs between 12 and 18, meaning one person can spread it to 12 to 18 others, a transmission rate high enough that public health teams treat a single confirmed case as urgent rather than waiting to see if it spreads further. Get 95 percent of a community vaccinated and R0 drops to about 1, which usually stops an outbreak in its tracks.

Symptoms

The illness follows a predictable pattern. Fever first. Then the rash.

About 7 to 21 days after exposure, early symptoms show up: high fever, cough, runny nose, red and watery eyes. Two or three days later, tiny white spots called Koplik spots can appear inside the mouth. By days 3 to 5 of illness, a red rash spreads from the face and hairline down the body, sometimes raised in the center, often with the fever spiking again at the same time.

Why It’s Serious

Complications are common. Pneumonia is the leading cause of death from measles. About one in a thousand people develops encephalitis, or brain inflammation, which can cause seizures or permanent damage. Severe diarrhea can cause dehydration. In rare cases, blindness or hearing loss occur.

There’s also a delayed complication called subacute sclerosing panencephalitis, a chronic infection of the central nervous system that shows up 6 to 8 years after measles. Symptoms include weakness, tremors, difficulty walking, and eventually coma. It is progressive and untreatable.

Infants, pregnant patients, and people with weak immune systems are at highest risk.

Diagnosis and Treatment

Diagnosis is usually confirmed by blood testing for IgM antibodies, which indicate recent infection. Respiratory swabs from the nose and throat can also detect measles RNA by PCR testing. Sometimes urine is tested as well.

There is no direct antiviral therapy. Treatment is supportive: keeping patients hydrated, managing fever and discomfort with acetaminophen or ibuprofen, and in children, supplementing with vitamin A. The virus lowers vitamin A levels in the body, and supplementing helps reduce the risk of severe complications.

What To Do if Someone Gets Measles

Isolation is critical. A patient should stay isolated for at least four days after the rash appears. Family and close contacts should be alerted. Post-exposure prophylaxis is an option for people who are unvaccinated or whose immunity is uncertain. The MMR vaccine may help if given within 72 hours of exposure. If that’s not possible, immune globulin (IVIG) within 6 days is another option, though the two should not be given together.

Complications need close monitoring. Breathing trouble, high fever that does not improve, or neurological symptoms should trigger immediate medical evaluation.

Prevention

The MMR vaccine is the most effective protection we have. Two doses run about 97 percent effective. Children should get their first dose at 12 to 15 months and the second between ages 4 and 6. Adults without immunity should receive at least one dose, and during outbreaks, infants as young as 6 months may be vaccinated early.

Vaccination protects the person who gets it. It also protects those who can’t get vaccinated themselves, including babies too young for the series and patients with immune conditions that rule out live vaccines. Stopping an outbreak for good takes at least 95 percent community coverage.

Closing

The 2025 measles outbreak showed how quickly this virus can return when vaccination coverage drops. Recognizing symptoms early, isolating cases, and vaccinating remain the keys to controlling it. As healthcare providers, we need to keep talking with patients about the value of the MMR vaccine and stay proactive about reporting and diagnosing cases.

For more information, visit the CDC’s measles page.

Related Reading

Measles Is Back: What Urgent Care and Telemedicine Clinicians Need to Watch For The Viral Rash: Exanthem Is Pertussis Contagious? Symptoms and Treatment Explained

Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.

Sources

Tuberculosis in 2025: Kansas Outbreak, Vaccines, and Staying Safe

Tuberculosis is still very much with us. Kansas dealt with a large outbreak in 2025, a reminder of how persistent this disease can be. As of January 2025, more than 67 active cases had been confirmed, mostly in Wyandotte and Johnson counties. There were fatalities, and the number of latent infections was rising at the time. Public health teams worked hard to contain it. It’s a reminder that TB remains a threat in both high-risk groups and the general population.

What TB Is

TB is caused by Mycobacterium tuberculosis. It usually attacks the lungs, but it doesn’t stop there: it can affect the brain, kidneys, spine, and other organs. It spreads through the air when someone with active TB coughs, sneezes, or even talks, and people nearby can breathe in the bacteria without realizing it.

Symptoms and Progression

The first signs can be subtle. A cough that won’t go away, maybe three weeks or more. Some patients cough up blood or sputum. Chest pain, fatigue, fever, night sweats, loss of appetite, and unexplained weight loss are common. Left untreated, TB can destroy lung tissue and spread further, causing meningitis, bone infection, or failure of multiple organs.

Latent vs Active

It’s important to separate latent TB from active disease. Latent TB means the bacteria are present but not causing illness. The person has no symptoms and is not contagious. But the bacteria can “wake up,” especially if the immune system gets weaker, and turn into active TB.

Active TB means the bacteria are multiplying, symptoms are present, and the patient can spread it to others. That’s the form that requires urgent treatment.

How It’s Detected

Testing matters. The skin test (the PPD or tuberculin test) is still used. A small injection under the skin, and the site is checked in 48 to 72 hours. Blood tests like QuantiFERON-TB Gold or T-SPOT.TB are often preferred, especially for people who got the BCG vaccine, since it can interfere with skin test results.

If TB is suspected, chest imaging can show lung changes, and sputum culture confirms the presence of M. tuberculosis. That culture is the gold standard for diagnosis in someone with symptoms.

The Role of the BCG Vaccine

The only vaccine we have is BCG. It’s mostly given to infants in countries where TB is widespread. It helps protect children from the most severe forms of TB, like meningitis, but it’s less effective at preventing pulmonary TB in adults. In the United States, it’s not routinely used because of its limited impact on adult disease and the way it interferes with skin testing.

Some healthcare workers in high-risk settings or people with repeated exposure may still receive it.

Protecting Against TB

Vaccination isn’t the whole answer for TB. Early detection and treatment carry just as much weight, maybe more. People at higher risk should be screened regularly, and treating latent TB is critical, because it stops progression to active disease.

Simple steps help too: masks in healthcare settings, good airflow in crowded places, covering your mouth when you cough, washing your hands regularly. During outbreaks, N95 or P100 respirators are the masks that actually filter TB bacteria from the air. Surgical masks don’t provide the same protection.

Treatment and Why It Has to Be Completed

TB can be treated, but it takes time. Standard therapy is multiple antibiotics for six to nine months. Isoniazid, rifampin, ethambutol, and pyrazinamide are the most commonly used.

Stopping treatment too soon is dangerous, because that’s exactly how drug-resistant TB develops, and multidrug-resistant TB is much harder to treat, far more expensive, and comes with worse outcomes across the board. An incompletely treated patient is also still contagious. Public health departments often use directly observed therapy, or DOT, where someone watches patients take their medications. It might sound strict, but it works. It prevents resistance and saves lives.

Public Health and What’s Next

TB is a problem here at home, and the outbreak in Kansas proves it. It spreads any time we let our guard down. Healthcare providers need to push for routine testing in high-risk groups, make sure patients complete treatment, and support public health efforts.

Patients and communities have a role too: stay informed, recognize symptoms, seek evaluation early. And we need continued research into better vaccines and treatments.

Related Reading

Tuberculosis: A Growing Problem in the Seattle Area Antibiotic Resistance Could End Modern Medicine, WHO Warns Is Pertussis Contagious? Symptoms and Treatment Explained Pneumonia: Viral, Bacterial or Walking? Am I at Risk?

Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.

Sources

Running water from a tap at a bathroom sink while washing hands

Flu Prevention: Vaccines, Symptoms, and Treatment Options

Influenza causes major illness every year despite vaccines and treatment options. The 2024-2025 season was a busy one. By mid-January 2025, the CDC had reported over 10 million flu-related illnesses and about 120,000 hospitalizations, numbers that ran ahead of the prior year. Flu season typically peaks between December and February. That swing from year to year reminds us how much flu activity depends on strain changes, how many people get vaccinated, and what immunity looks like across the population.

Why History Matters

Flu is not new. The 1918-1919 pandemic killed an estimated 50 million people worldwide. Three later pandemics, in 1957, 1968, and 2009, each showed how dangerous a new strain can be. Every one of them pushed public health toward stronger vaccines, better antivirals, and better surveillance.

Public Health Impact

Every year influenza causes between 290,000 and 650,000 deaths worldwide. Young children, older adults, pregnant people, and those with chronic conditions carry the most risk. Flu season also strains hospitals and clinics, and it costs billions in missed workdays and healthcare spending on top of the direct health toll.

How Flu Spreads

The incubation period is short, usually about two days. Transmission happens through droplets, when people cough, sneeze, or talk, and through contaminated surfaces if someone touches their face afterward. In households and schools, attack rates can reach 20 to 30 percent.

People can spread flu a full day before symptoms start, and for up to a week after. Immunocompromised patients can spread it longer than that.

Symptoms and Complications

Classic symptoms are fever, cough, sore throat, body aches, fatigue, and headache. Children are more likely than adults to get vomiting or diarrhea along with it.

For most people the illness runs its course. But complications are common enough to take seriously: secondary bacterial pneumonia, worsening asthma or COPD, myocarditis, encephalitis, even ARDS. These are the cases that fill hospital beds every winter.

Influenza A and B

Both influenza A and B drive seasonal flu, but they behave differently. Influenza A is more common, infects humans and animals, and is behind pandemics. Subtypes like H1N1 and H3N2 are defined by their surface proteins. Influenza B only infects humans, and it has two main lineages, Victoria and Yamagata. Outbreaks from influenza B tend to be smaller but still cause serious illness, especially in children. A often dominates earlier in the season, while B shows up later, though they can circulate together.

Diagnosis

Most of the time, diagnosis starts clinically. But testing can confirm it. Rapid tests give results in about 15 minutes, though sensitivity is limited. RT-PCR is much more accurate and is considered the gold standard.

Vaccination

The flu vaccine changes yearly to match expected strains. For 2024-2025, the U.S. vaccine was trivalent, not quadrivalent: two influenza A strains, H1N1 and H3N2, and one influenza B strain, Victoria. B/Yamagata was left out of that season’s formulation, per the CDC’s ACIP recommendations, because global surveillance had not detected it since 2020.

Effectiveness runs 40 to 60 percent, depending on the match and the patient’s age and health. Vaccines come in several forms: inactivated injectable, live attenuated nasal spray, and higher-dose or adjuvanted versions for older adults.

Treatment

Antivirals work best started within 48 hours of symptoms. Oseltamivir is oral and the one used most. Zanamivir is inhaled, peramivir is intravenous and usually reserved for hospitalized patients, and baloxavir is a single-dose oral option that blocks replication.

Supportive care still matters most: rest, fluids, acetaminophen or ibuprofen for fever and pain, and close monitoring for complications in anyone at higher risk.

Prevention

Annual vaccination is the best prevention. Handwashing, covering coughs, staying home when sick, and avoiding close contact with ill people all reduce spread. Masks and improved ventilation are useful in crowded settings, especially when flu activity runs high.

Final Notes

Flu is not going away. Each season differs, but the tools we have (vaccines, antivirals, good hygiene, early recognition) make a real difference when used consistently. As physicians, we need to push vaccination, treat high-risk patients early, and keep reminding our communities that influenza is more than “just a cold.”

Related Reading

Cold vs Flu vs COVID vs RSV: How to Tell Them Apart Human Metapneumovirus (hMPV): What You Need to Know H5N1 Bird Flu: What Every Patient Should Know Today Norovirus Illness: What Patients and Doctors Need to Know 2026-2027 COVID Vaccine: Who Qualifies, and Do You Need a Doctor’s Note? Why Won’t Antibiotics Cure a Viral Infection? Doctor Explains

Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.

Sources

  • Centers for Disease Control and Prevention. FluView Surveillance. https://www.cdc.gov/fluview/surveillance/index.html
  • World Health Organization. Influenza (Seasonal). https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal))
  • Dawood FS, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687-695. PMID 22738893.
  • Grohskopf LA, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2024-25 Influenza Season. MMWR Recomm Rep. 2024;73(RR-5):1-25. PMID 39197095.

Is Pertussis Contagious? Symptoms and Treatment Explained

Pertussis, or whooping cough, made a comeback in 2024. Outbreaks were reported in different regions around the world, and the United States was no exception, with cases rising for several years running despite decades of vaccination effort, and in 2024 there were more than 35,000 reported cases, higher than what we’d typically seen over the prior decade. Some of that traces to waning vaccine immunity, incomplete vaccine schedules, and vaccine hesitancy. Schools were a particular hotspot, especially among older children and adolescents who had missed boosters.

This isn’t a new story. In the early 20th century, pertussis was one of the leading causes of death in children. In the 1920s and 1930s, hundreds of thousands of cases occurred every year in the U.S., and fatality rates in infants sometimes reached 5 to 10 percent. Families often saw multiple children get sick at the same time. Hospitals had few tools to help. No antibiotics. No vaccines. Isolation was the only real measure available, and it wasn’t enough.

The arrival of the first whole-cell vaccine in the 1940s changed the picture, and by the 1950s and 60s, pertussis cases had dropped by more than 90 percent. It went from a routine killer to something most doctors rarely saw. But the drop didn’t mean it disappeared; over time, as immunity fades and vaccine uptake slips, the disease resurfaces.

What Pertussis Does in the Body

The cause is Bordetella pertussis, a gram-negative bacterium discovered in 1906. It attaches to the airway lining using adhesion proteins and releases toxins that damage the respiratory tract and disrupt the immune response. Pertussis toxin, adenylate cyclase toxin, and tracheal cytotoxin are some of the key players, and together they paralyze cilia, create thick mucus, and inflame the airways. That’s what sets up the violent coughing fits and the difficulty clearing secretions.

The incubation period is usually 5 to 10 days but can stretch out to 3 weeks, and transmission is mainly through droplets when people cough, sneeze, or talk, though it can also spread indirectly through contaminated surfaces.

The Course of Illness

Pertussis has three stages. The first, the catarrhal stage, looks a lot like a cold. Patients may have mild cough, runny nose, and low-grade fever. But this is also the most contagious stage, and infants in this stage can suddenly stop breathing or develop pneumonia.

After one to two weeks, the paroxysmal stage begins, the coughing fits severe, sometimes so prolonged that patients vomit or become exhausted. The classic “whoop” happens when the patient forcefully inhales after running out of breath. This stage can last weeks.

Finally comes the convalescent stage. Symptoms ease, but the cough may linger for months, and infants are at the highest risk of complications throughout, including pneumonia, seizures, and encephalopathy.

How Long People Are Contagious

Without treatment, a person with pertussis can remain infectious for weeks, often up to three weeks into the paroxysmal stage. With antibiotics, contagiousness drops significantly after five days of therapy.

Diagnosing Pertussis

Clinical suspicion is usually the first step. The cough pattern and exposure history often give it away. PCR testing is the most rapid and sensitive diagnostic method now, while culture is still considered the gold standard, though rarely used because it takes longer and needs special media. Serology may help later in the illness.

Treatment and Timing

Macrolides like azithromycin are first-line treatment, with trimethoprim-sulfamethoxazole an option if macrolides can’t be used. Antibiotics are most effective early, ideally in the catarrhal stage, but they’re still useful later to limit spread.

The CDC recommends treating patients within three weeks of cough onset if they’re over a year old, within six weeks for infants under one, and also within six weeks for pregnant women close to delivery. Supportive care, hydration, rest, and monitoring, is especially important for infants, who may need hospitalization.

Post-Exposure Prophylaxis

Preventing spread matters just as much as treating active cases, and giving antibiotics to close contacts can stop the chain. This is particularly recommended for infants under 12 months, pregnant women in their third trimester, and household members or healthcare workers exposed to confirmed cases. Timing matters: post-exposure prophylaxis should start within 21 days of exposure.

Prevention and Vaccination

Vaccination is still the strongest defense. The childhood DTaP series provides good protection early on, though immunity fades over time. About 98 percent of children are immune one year after their last DTaP dose, but that drops to around 70 percent five years later. That’s why boosters are needed.

The Tdap booster is given at 11 or 12 years of age, again in adulthood every 10 years, and during each pregnancy between 27 and 36 weeks. Protection from Tdap is estimated at about 73 percent in the first year and 34 percent after four years. This waning immunity is a major factor in outbreaks.

Public health responses focus on quick recognition, isolation of cases, prophylaxis for contacts, and community education, and mask use, hand hygiene, and cleaning surfaces all help reduce spread.

Why Vigilance Matters

Pertussis is not a disease of the past. It’s resurging in part because immunity doesn’t last forever, and physicians need to recognize it early and treat aggressively, while patients and families need to keep vaccination schedules up to date. When that doesn’t happen, infants and medically fragile patients pay the highest price.

Related Reading

Whooping Cough Epidemic Spreads Across Washington State Measles in 2025: What Patients and Providers Need to Know Measles Is Back: What Urgent Care and Telemedicine Clinicians Need to Watch For Why Won’t Antibiotics Cure a Viral Infection? Doctor Explains My Child Has a Barking Seal-like Cough: Is It Croup?

Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.

Sources

  • Centers for Disease Control and Prevention. Pertussis (Whooping Cough). https://www.cdc.gov/pertussis
  • Cherry JD. The science and fiction of the “resurgence” of pertussis. Pediatrics. 2003;112(2):405-406. PMID 12897292.
  • American Academy of Pediatrics. Red Book: 2021–2024 Report of the Committee on Infectious Diseases.
  • Clark TA. Changing pertussis epidemiology: Everything old is new again. J Infect Dis. 2014;209(7):978-981. PMID 24626532.
A box of tissues on a container beside a window

Human Metapneumovirus (hMPV): What You Need to Know

Human metapneumovirus, or hMPV, doesn’t get the same attention as influenza or COVID-19, but it’s worth understanding. It was first identified in 2001, though genetic studies suggest it has circulated for decades, and it’s a member of the Paramyxoviridae family, the same family that includes RSV.

Transmission is through respiratory droplets. That means coughing, sneezing, or close contact with an infected person is usually how it spreads, and anyone can get it, though young children, older adults, and people with weakened immune systems are most vulnerable to severe illness.

Where It Shows Up

hMPV is found worldwide. It circulates throughout the year but tends to spike in late winter and spring in temperate regions, and improved diagnostics over the last two decades have shown just how common it is. Clusters show up in schools, childcare centers, nursing homes, and hospitals. Often alongside influenza and RSV activity.

In the United States, the CDC tracks it as part of routine respiratory surveillance, and globally, WHO lists it as one of several viruses contributing to seasonal surges of respiratory illness.

Symptoms and Overlap

The symptoms of hMPV are familiar. Patients may have fever, cough, sore throat, congestion, fatigue, and sometimes wheezing, and in healthy people, illness usually resolves within one to two weeks. In infants, older adults, or immunocompromised patients, the disease can progress to bronchiolitis or pneumonia.

The overlap with RSV, influenza, and COVID-19 makes it nearly impossible to identify clinically without testing, and in practice, we often don’t test unless patients are hospitalized or part of an outbreak under investigation.

Why It Matters

Most patients recover with supportive care. But hMPV deserves attention for a few reasons: high-risk populations can become severely ill enough to need hospitalization. Unlike flu or COVID-19, there’s no vaccine and no specific antiviral, so care stays supportive: oxygen, fluids, symptom management. And hMPV adds to the seasonal burden on the system overall, and when it circulates alongside RSV and flu, pediatric and ICU beds can fill fast.

Current Reports

China had reported more cases the previous winter, mostly among children under 14 in northern provinces. The increase triggered heightened monitoring at the time, though local health authorities noted the pattern was typical for the season and not as severe as the same period the year before. The WHO emphasized that hMPV is a known virus, not a new or emerging threat, and said it did not represent a global health emergency.

What To Watch For

For physicians, it comes down to clinical awareness. If a patient has unexplained respiratory illness, especially if they’re very young, older, or immunocompromised, consider hMPV in the differential. For patients, the message is simple: good hygiene matters, and wash hands, avoid close contact when sick, and stay home if you’re symptomatic. These are the same steps that help reduce spread of other respiratory viruses.

hMPV doesn’t carry the same weight as influenza or COVID-19, but it plays a consistent role in seasonal respiratory disease, and understanding it helps us manage patients more effectively and prepare for the extra strain it can place on hospitals during peak months.

Related Reading

Flu Prevention: Vaccines, Symptoms, and Treatment Options 2026-2027 COVID Vaccine: Who Qualifies, and Do You Need a Doctor’s Note? Why Won’t Antibiotics Cure a Viral Infection? Doctor Explains Wheezing and Possible Asthma: What Should You Do Next?

Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.

Sources